XFOR — X4 Pharmaceuticals Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About X4 Pharmaceuticals Inc

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$4.04
Market Cap$356M
Float57.4M
Shares Outstanding94.3M
Price/Sales (TTM)39.45
vs. Analyst Target+188.8% to analyst PT
Operating Margin (TTM)-748.49%
Revenue (TTM)$9.0M
Dividend RateNone
Analyst Target Price$11.67 (5 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $3.0M -$62.1M $3.0M -$59.5M
2021 N/A -$88.7M -$1.9M -$73.5M
2022 N/A -$93.9M -$2.0M -$89.3M
2023 N/A -$101M -$2.0M -$94.9M
2024 $2.6M -$37.5M $1.8M -$27.6M
2025 $35.1M -$79.2M $28.9M -$85.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $2.0M -$25.7M
Sep 2025 $1.8M -$29.8M
Dec 2025 $2.6M -$23.9M
Mar 2026 $2.7M -$20.2M

Ownership & Float

Insider Ownership0.6%
Institutional Ownership99.6%
Short Float5.4%
% of All Funds Holding0.91%
Number of Funds Holding75

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$4.17Near-term / short-term trend
Weekly40-Week SMA$3.77Medium-term trend
Weekly80-Week SMA$6.36Cyclical trend (business cycle)
Weekly200-Week SMA$22.93Secular trend (multi-year)
Monthly10-Month SMA$3.82Near-term monthly trend
Monthly20-Month SMA$6.91Medium-term monthly trend
Monthly40-Month SMA$19.84Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$1.60 support 7.62x 8 months ago
$6.90 resistance 1.10x 12 months ago
$30.00 resistance 1.11x 22 months ago
$42.00 resistance 1.85x 24 months ago

Historical Earnings Reactions (35 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.37% 0.35% 60.00% 10.11% -11.70%
1 Day 2.30% -0.67% 45.71% 48.01% -7.99%
1 Week 6.44% 3.36% 60.00% 67.11% -11.97%
2 Weeks 14.42% 2.19% 51.43% 200.73% -22.13%
1 Month 13.16% 0.65% 50.00% 172.99% -45.50%

Next earnings: May 7, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan-1.1%33.3%9
Feb0.8%55.6%9
Mar8.5%55.6%9
Apr-2.5%22.2%9
May-4.1%25.0%8
Jun-26.9%12.5%8
Jul-4.0%25.0%8
Aug7.5%37.5%8
Sep-0.2%25.0%8
Oct-8.4%25.0%8
Nov16.1%25.0%8
Dec-5.0%44.4%9

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.69% 42.5% 400
Tuesday 0.77% 40.7% 440
Wednesday -0.26% 46.3% 436
Thursday 0.06% 46.3% 428
Friday 0.07% 45.3% 430

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 99.6%

Insider Transactions — Smart Summary

Total insider ownership: 0.6%

12-Month Insider Activity Summary

Total Filings2
Net Value+$177,177.043
Net Shares Change69,245
% of Float0.1%
C-Suite Filings2
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Craig Adam R Executive Chairman +$249,997.4 1 1 buy
KIRSKE DAVID Chief Financial Officer -$72,820.357 1 1 sell

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-05-13 KIRSKE DAVID Chief Financial Officer -$72,820.357 Transaction at $4.29, now -5.9%
2025-10-27 Craig Adam R Executive Chairman +$249,997.4 Transaction at $2.90, now +39.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for X4 Pharmaceuticals Inc (XFOR) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for XFOR on Trend Edge →